Cardiol Therapeutics Inc (CRDL) Opciones

NASDAQ: $CRDL SHORT SQUEEZE ALERTS

Financial Strategy: With about $21 million in cash, the company may consider a small capital raise if new data boosts the stock price, aiming for a target of $10 per share (C$13.60

NASDAQ: $CRDL

Cardiol Therapeutics MAvERIC-Pilot Study Results:

Safety: High tolerability and 95% compliance.

Next Steps: Data supports advancing to Phase II/III MAVERIC-2 and Phase III MAVERIC-3 trials

A target of $10 per share (approximately C$13.60) is proposed, indicating a potential upside of over 5x within a year, contingent on strong data readouts for CardiolRx™?

NASDAQ: $CRDL

Advancement: Results support Phase II/III MAVERIC-2 and Phase III MAVERIC-3 trials, expanding accessibility to non-immunosuppressive oral therapy.

Short Squeeze Alerts $CRDL, BIG OPPORTUNITY

NASDAQ: $CRDL

Cardiol Therapeutics sets a 12-month price target of $10, valuing CardiolRx at $9 for recurrent pericarditis and $1 for acute myocarditis, based on projected sales and associated probabilities.

NASDAQ: $CRDL Pick Up This Morning Short Sueeze Aler

 MAvERIC-Pilot Results:
Safety: High tolerance, 95% compliance.
Next Steps: Advancing to Phase II/III MAVERIC-2 and Phase III MAVERIC-3 trials

NASDAQ: $CRDL MAvERIC-Pilot Study:

Efficacy: Significant reductions in pericarditis pain (mean score 5.8 to 1.5) and inflammation (CRP normalized in 80% of patients). Episodes dropped from 5.8/year to 0.9 during the trial.

Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024

INSIDER BUYING : Cardiol CEO David Elsley purchased approximately $100,000 in shares at about $2.03 each, indicating strong personal conviction in the company's potential.

$CRDL Here are the MAvERIC-Pilot study results that we’ve been waiting for! 

❤️Marked and rapid reductions in both pericarditis pain and inflammation  maintained throughout the 26-week study!

❤️Episodes of pericarditis per year substantially reduced 

❤️MAvERIC-Pilot results support advancing CardiolRx™ into the Phase II/III MAVERIC-2
and the Phase III MAVERIC-3 clinical trials

Congratulations to all long term shareholders! 

NASDAQ: $CRDL BIG NEWS:

Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024

Breaking News: NASDAQ: $CRDL unveils groundbreaking results for CardiolRx™ at the American Heart Association Conference! 📷 Rapid pain relief, 85% fewer recurrences, and lasting inflammation reduction.

NASDAQ: $CRDL 12-Month Price Target: $10 based on a sum-of-the-parts valuation.

Valued at $9 per share, assuming $609M in sales

Valued at $1 per share, assuming $132M in sales

NASDAQ: $CRDL RED TO GREEN, Looks Good

Cardiol Therapeutics Inc Today at 11:15am EST Dr. Allen Luis MayoClinic will present the Pericarditis full clinical data at #AHA2024

NASDAQ: $CRDL SHORT SQUEEZE ALERTS, STAY TUNED

Addressing urgent unmet medical needs: CardiolRx™ targets acute myocarditis, a life-threatening condition with no FDA-approved treatments

NASDAQ: $CRDL 12-Month Price Target: $10 based on a sum-of-the-parts valuation.

 Valued at $9 per share, assuming $609M in sales by 2033

Valued at $1 per share, assuming $132M in sales by 2033

NASDAQ: $CRDL The 12-month price target is $10, with $9 attributed to recurrent pericarditis and $1 to acute myocarditis

Recently raised $13.5 million to fund developments?, SHORT SQUEEZE ALERTS

NASDAQ: $CRDL lets See Red To Green, 

H.C. Wainwright maintains a "Buy" rating for Cardiol Therapeutics with a price target of $9.00.

The company recently raised $13.5 million

NASDAQ: $CRDL The company recently raised $13.5 million, ensuring financial backing for ongoing clinical developments and corporate growth

Picked up NASDAQ: $CRDL this morning…low float runner on news incoming… Short Squeeze Alerts

The 12-month price target is $10, with $9 attributed to recurrent pericarditis and $1 to acute myocarditis

30 million shares offering at .26 October 30th

H.C. Wainwright maintains a "Buy" rating for Cardiol Therapeutics with a price target of $9.00.

MAVERIC-2 trial aims to assess CardiolRx in recurrent pericarditis patients post-IL-1 blocker therapy.

$CRDL up over 220% year-to-date; analysts raised the price target from $4.50 to $11.00, keeping a "Speculative Buy" rating.

NASDAQ: $CRDL SHORT SQUEEZE ALERTS

H.C. Wainwright maintains a "Buy" rating for Cardiol Therapeutics with a price target of $9.00.

MAVERIC-2 trial aims to assess CardiolRx in recurrent pericarditis patients post-IL-1 blocker therapy.

NASDAQ: $CRDL Financial Strategy: With about $21 million in cash, the company may consider a small capital raise if new data boosts the stock price,aiming for a target of $10 per share (C$13.60

Key Points:

Rating & Price Target: H.C. Wainwright maintains a "Buy" rating for Cardiol Therapeutics (CRDL) with a price target of $9.00.
New Trial: MAVERIC-2 trial aims to assess CardiolRx in recurrent pericarditis (RP) patients post-IL-1 blocker therapy.
Market Advantage: CardiolRx could serve as an earlier treatment alternative, competing with Arcalyst, which costs $300,000 annually.
Strategic Expansion: By targeting unmet needs in the RP market, CardiolRx is positioned to broaden its market potential.

NASDAQ: $CRDL up over 220% year-to-date; analysts raised the price target from $4.50 to $11.00, keeping a "Speculative Buy" rating.

Recently raised $13.5 million to fund developments?

Big coming Next week 💃💃💃💃

NASDAQ: $CRDL
ARCHER trial completed enrollment, with results expected in Q1 2025. Orphan status could lead to $120M peak sales 

Promising early results, potential approval by 2027, targeting $609M peak sales

NASDAQ: $CRDL With about $21 million in cash, the company may consider a small capital raise if new data boosts the stock price, aiming for a target of $10 per share (C$13.60

$CRDL BIG SHORT SQUEEZE 

Chart looking good $2.07 next targets $4

CRDL........................https://stockcharts.com/h-sc/ui?s=CRDL&p=W&b=5&g=0&id=p86431144783

NASDAQ: $CRDL sets a 12-month price target of $10, valuing CardiolRx at $9 for recurrent pericarditis and $1 for acute myocarditis, based on projected sales and associated probabilities.

NASDAQ: $CRDL up over 220% year-to-date; analysts raised the price target from $4.50 to $11.00, keeping a "Speculative Buy" rating.

NASDAQ: $CRDL 12-Month Price Target: $10 based on a sum-of-the-parts valuation.

Cardiol had around $21 million in cash at the end of Q1 

NASDAQ: $CRDL
 Cardiol Therapeutics recently reported encouraging outcomes from its Phase II MAvERIC trial of CardiolRx, an ultra-pure oral cannabidiol formulation for recurrent pericarditis.

The 12-month price target is $10

NASDAQ: $CRDL Cardiol Therapeutics sets a 12-month price target of $10, valuing CardiolRx at $9 for recurrent pericarditis and $1 for acute myocarditis, based on projected sales and associated probabilities.

NASDAQ: CRDL is advancing CardiolRx™ for acute myocarditis and recurrent pericarditis, both in Phase II trials. The company raised $13.5 million

NASDAQ: $CRDL CEO Investment: Cardiol CEO David Elsley purchased approximately $100,000 in shares at about $2.03 each, indicating strong personal conviction in the company's potential.

NASDAQ: $CRDL With about $21 million in cash, the company may consider a small capital raise if new data boosts the stock price, aiming for a target of $10 per share (C$13.60

NASDAQ: $CRDL is advancing CardiolRx™ for acute myocarditis and recurrent pericarditis, both in Phase II trials. The company raised $13.5 million

NASDAQ: $CRDL A target of $10 per share (approximately C$13.60) is proposed, indicating a potential upside of over 5x within a year, contingent on strong data readouts for CardiolRx™?

Cardiol Therapeutics sets a 12-month price target of $10, valuing CardiolRx at $9 for recurrent pericarditis and $1 for acute myocarditis, based on projected sales and associated probabilities.

$CRDL Insider Buying: Cardiol CEO David Elsley purchased approximately $100,000 in shares at about $2.03 each

NASDAQ: $CRDL Cardiol Therapeutics sets a 12-month price target of $10, valuing CardiolRx at $9 for recurrent pericarditis and $1 for acute myocarditis, based on projected sales and associated probabilities

NASDAQ: $CRDL 12-month price target is $10, with $9 attributed to recurrent pericarditis and $1 to acute myocarditis

NASDAQ: $CRDL is advancing CardiolRx for acute myocarditis and recurrent pericarditis, both in Phase II trials. The company raised $13.5 million

Cardiol sets a 12-month price target of $10

NASDAQ: $CRDL Short Squeeze Allerts 

A target of $10 per share (approximately C$13.60) is proposed, indicating a potential upside of over 5x within a year, contingent on strong data readouts for CardiolRx™?

Volume looks GOOD 💃💃🚀

NASDAQ: $CRDL Valuation: The 12-month price target is $10, with $9 attributed to recurrent pericarditis and $1 to acute myocarditis

PICK UP $CRDL THIS MORNING